2Yoshizaki K, Matsuda T, Nishimoto N, et al. Pathogenic signifi- cance of interleukin-6 (IL-6/BSF-2) in Castleman ' s disease. Blood, 1989, 74: 1360-1367. 被引量：1
3Ishiyama T, Koike M, Nakamura S, et al. Interleukin-6 receptor expression in the peripheral B cells of patients with muhicentric Cast|eman' s disease. Ann Hematol, 1996, 73 : 179-182. 被引量：1
4Brandt SJ, Bodine DM, Dunbar CE, et al. Retroviral-mediatedtransfer of interleukin-6 into hematopoietic cells of mice results in a syndrome resembling Castleman' s disease. CmT Top Microbiol Immunol, 1990, 166: 37-41. 被引量：1
5Brandt SJ, Bodine DM, Dunbar CE, et al. Dysregulated interleu- kin 6 expression produces a syndrome resembling Castleman' s disease in mice. J Clin Invest, 1990, 86: 592-599. 被引量：1
6Nishimoto N, Kishimoto T. Interleukin 6: from bench o bedside. Nat Clin Pract Rheumatol, 2006, 2:619-626. 被引量：1
7Oksenhendler E, Carcelain G, Aoki Y, et al. High levels of human herpes virus 8 viral load, human interleukin-6, interleu- kin-10, and C reactive protein correlate with exacerbation of muhicentric Castleman disease in HIV-infected patients. Blood, 2000, 96:2069-2073. 被引量：1
8Foussat A, Fior R, Girard T, et al. Involvement of human inter- leukin-6 in systemic manifestations of human herpes virus type 8-associated multicentric Castleman' s disease. AIDS, 1999, 13 : 150-152. 被引量：1
9Nishimoto N, Sasai M,Shin~a Y,et al. Improvement in Castleman' s disease by humanized anti-interleukin-6 receptor antibody therapy. Blood, 2000, 95: 56-61. 被引量：1
10Nishimoto N, Kanakura Y, Aozasa K, et at. Humanized anti- interleukin-6 receptor antibody treatment of multicentric Castleman disease. Blood, 2005, 106: 2627-2632. 被引量：1
